Abstract
Background: Pridopidine, a compound in clinical trials for Huntington's disease treatment, was originally synthesized as a dopamine D2 receptor (D2R) ligand, but later found to possess higher affinity for the sigma-1 receptor (S1R). However, the putative contributions of D2R and S1R to the behavioral profile of acutely administered pridopidine have not been investigated.
Objective: The present study sought to compare the effects of acute pridopidine on wild-type vs. D2R and S1R knockout mice, at high (60 mg/kg) and low (6 mg/kg) doses.
Method: Pridopidine effects on basal and phencyclidine-induced locomotor activity was measured in the open field test. Additionally, the actions of pridopidine on prepulse inhibition was measured in animals treated with saline or phencyclidine.
Results: Whereas inhibition of spontaneous and phencyclidine-induced locomotion was readily observed at 60 mg/kg pridopidine, neither locomotor stimulation in habituated mice, nor any effects on prepulse inhibition were detected upon pridopidine treatment. Surprisingly, inhibition of spontaneous locomotion was unaffected by both D2R and S1R deletion.
Conclusion: The present results suggest the involvement of additional targets, besides D2R and S1R, in mediating locomotor inhibition by pridopidine.
Keywords: Sigma-1 receptor, dopamine receptor, knockout mice, phencyclidine, open field, prepulse inhibition.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Effects of the Dopamine Stabilizer, Pridopidine, on Basal and Phencyclidine-Induced Locomotion: Role of Dopamine D2 and Sigma-1 Receptors
Volume: 17 Issue: 7
Author(s): Kristoffer Sahlholm*, Marta Valle-Leon, Jaume Taura, Victor Fernandez-Duenas and Francisco Ciruela*
Affiliation:
- Unitat de Farmacologia, Departament Patologia i Terapeutica Experimental, Facultat de Medicina i Ciencies de la Salut, IDIBELL-Universitat de Barcelona, L`Hospitalet de Llobregat, Barcelona,Spain
- Unitat de Farmacologia, Departament Patologia i Terapeutica Experimental, Facultat de Medicina i Ciencies de la Salut, IDIBELL-Universitat de Barcelona, L`Hospitalet de Llobregat, Barcelona,Spain
Keywords: Sigma-1 receptor, dopamine receptor, knockout mice, phencyclidine, open field, prepulse inhibition.
Abstract: Background: Pridopidine, a compound in clinical trials for Huntington's disease treatment, was originally synthesized as a dopamine D2 receptor (D2R) ligand, but later found to possess higher affinity for the sigma-1 receptor (S1R). However, the putative contributions of D2R and S1R to the behavioral profile of acutely administered pridopidine have not been investigated.
Objective: The present study sought to compare the effects of acute pridopidine on wild-type vs. D2R and S1R knockout mice, at high (60 mg/kg) and low (6 mg/kg) doses.
Method: Pridopidine effects on basal and phencyclidine-induced locomotor activity was measured in the open field test. Additionally, the actions of pridopidine on prepulse inhibition was measured in animals treated with saline or phencyclidine.
Results: Whereas inhibition of spontaneous and phencyclidine-induced locomotion was readily observed at 60 mg/kg pridopidine, neither locomotor stimulation in habituated mice, nor any effects on prepulse inhibition were detected upon pridopidine treatment. Surprisingly, inhibition of spontaneous locomotion was unaffected by both D2R and S1R deletion.
Conclusion: The present results suggest the involvement of additional targets, besides D2R and S1R, in mediating locomotor inhibition by pridopidine.
Export Options
About this article
Cite this article as:
Sahlholm Kristoffer *, Valle-Leon Marta , Taura Jaume , Fernandez-Duenas Victor and Ciruela Francisco *, Effects of the Dopamine Stabilizer, Pridopidine, on Basal and Phencyclidine-Induced Locomotion: Role of Dopamine D2 and Sigma-1 Receptors, CNS & Neurological Disorders - Drug Targets 2018; 17 (7) . https://dx.doi.org/10.2174/1871527317666180627103337
DOI https://dx.doi.org/10.2174/1871527317666180627103337 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Aripiprazole: A Drug with a Novel Mechanism of Action and Possible Efficacy for Alcohol Dependence
CNS & Neurological Disorders - Drug Targets Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Chemokine-Chemokine Receptor Network in Immune Cell Trafficking
Current Drug Targets - Immune, Endocrine & Metabolic Disorders α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Assessing Depression in Patients with an Acute Coronary Syndrome: A Literature Review
Current Psychiatry Reviews “Evaluation of the Association between Addiction Severity Index and Depression with Adherence to Anti-retroviral Therapy among HIV Infected Patients”
Infectious Disorders - Drug Targets The Ultra High Risk Approach to Define Psychosis Risk
Current Pharmaceutical Design Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease
Current Alzheimer Research Prevalence of Comorbid Anxiety Disorders in Schizophrenia Spectrum Disorders: A Literature Review
Current Psychiatry Reviews Review of Evidence-Based Psychotherapies for Pediatric Mood and Anxiety Disorders
Current Psychiatry Reviews Reactive Astrogliosis: Role in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters CGRP Receptor Antagonists: Toward a Novel Migraine Therapy
Current Pharmaceutical Biotechnology Intracardiac Origin of Heart Rate Variability, Pacemaker Funny Current and their Possible Association with Critical Illness
Current Cardiology Reviews Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences
Current Neuropharmacology Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis?
Recent Patents on Drug Delivery & Formulation